Evidence map›Paper›PMID 40758574›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2025

Loss of hepatocyte-specific RECK exacerbates metabolic dysfunction-associated steatohepatitis.

Ryan J Dashek, Taylor J Kelty, Rory P Cunningham, Jack Flink, Alexa A Krause, Grace Shryack, Christopher L Taylor, Grace M Meers, Tadashi Yoshida, Srinivas Mummidi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ryan J DashekResearch Service, Harry S. Truman Memorial Veterans Medical Center, Columbia, Missouri, United States.
Taylor J KeltyNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0003-1494-4830
Rory P CunninghamResearch Service, Harry S. Truman Memorial Veterans Medical Center, Columbia, Missouri, United States.
Jack FlinkNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.
Alexa A KrauseNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0002-6220-4741
Grace ShryackNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.
Christopher L TaylorResearch Service, Harry S. Truman Memorial Veterans Medical Center, Columbia, Missouri, United States.
Grace M MeersResearch Service, Harry S. Truman Memorial Veterans Medical Center, Columbia, Missouri, United States.
Tadashi YoshidaDepartment of Medicine and Physiology, School of Medicine, Tulane University, New Orleans, Louisiana, United States.ORCID 0000-0002-4544-1497
Srinivas MummidiLife Sciences, Texas A&M University-San Antonio, San Antonio, Texas, United States.
Bysani ChandrasekarResearch Service, Harry S. Truman Memorial Veterans Medical Center, Columbia, Missouri, United States.ORCID 0000-0002-8212-5354
R Scott RectorResearch Service, Harry S. Truman Memorial Veterans Medical Center, Columbia, Missouri, United States.ORCID 0000-0001-9908-7123

Funding

Postdoctoral Training in Comparative MedicineT32OD011126 · OD · UNIVERSITY OF MISSOURI-COLUMBIA · PI Elizabeth C Bryda, Aaron Ericsson · 2012 to 2026
$3.4M
RECK regulation of NASH and fibrosisR01DK130243 · NIDDK · UNIVERSITY OF MISSOURI-COLUMBIA · PI BYSANI, CHANDRASEKAR, RECTOR, RANDY SCOTT · 2022 to 2025
$2.2M
RECK as a Therapeutic Target for AtherosclerosisR01HL170056 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI Chandrasekar Bysani, Shiyou Chen · 2025 to 2026
$1.3M
BLRD VA I01 BX003271BLRD VA I01 BX005845BLRD VA IK6 BX004016BLRD VA IK6 BX007133HHS | National Institutes of Health (NIH) 2T32OD011126-43HHS | National Institutes of Health (NIH) R01DK130243-01A1NHLBI NIH HHS R01 HL170056NIDDK NIH HHS R01 DK130243NIH HHS T32 OD011126U.S. Department of Veterans Affairs (VA) 1IK6BX007133-01U.S. Department of Veterans Affairs (VA) IK6BX004016U.S. Department of Veterans Affairs (VA) VA Merit I01BX003271U.S. Department of Veterans Affairs (VA) VA Merit I01BX5845
6 · The paper itself

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) continues to be a major health crisis worldwide due to increases in obesity and insulin resistance. The role of the extracellular matrix regulator reversion-inducing cysteine-rich protein with Kazal motifs (RECK) in metabolic liver disease is poorly understood. We previously reported that RECK gain-of-function, specifically in hepatocytes, protects against diet-induced MASH. Here, we hypothesized that hepatocyte-specific RECK loss-of-function exacerbates liver injury in a preclinical model of diet-induced MASH. Using two novel mouse models of hepatocyte-specific RECK depletion, we demonstrate that

Indexed as

Fatty LiverGPI-Linked ProteinsHepatocytesNon-alcoholic Fatty Liver DiseaseAmphiregulinAnimalsDisease Models, AnimalErbB ReceptorsInflammationLiverLiver CirrhosisMaleMiceMice, Inbred C57BLMice, KnockoutProteomicsAmphiregulinAreg protein, mouseErbB ReceptorsGPI-Linked ProteinsReck protein, mouseamphiregulinepidermal growth factor receptorextracellular matrixmetabolic dysfunction-associated steatohepatitisreversion inducing cysteine rich protein with Kazal motifs

Identifiers

PMID40758574
PMCPMC12369582

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.